Episodes
-
Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available treatments for these patients.
They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF mutations, as well as the targeted therapies currently available for BRAF-mutated CRC.
Several key trials are discussed, including the BEACON trial which resulted in encorafenib plus cetuximab being the standard of care in the second-line setting for patients with BRAF mutated CRC.
The discussion also looks at future studies including the BREAKWATER trial, which will provide important information about encorafenib plus cetuximab in the first-line for these patients, as well as the SEAMARK trial which will show the effects of adding immunotherapy to this combination.
Key clinical takeaways:
BRAF mutations occur in around 10% of colorectal cancer patients and patients harbouring these have aggressive disease and a poor prognosis Targeted therapies are available for BRAF-mutated CRC so it is important to test patients early in their disease preferably with next-generation sequencing Encorafenib plus cetuximab are established as the standard of care in the second-line setting for BRAF-mutated CRC Doublet chemotherapy plus anti-VEGF is currently the preferred treatment in the first-line. The BREAKWATER trial will determine whether the combination of encorafenib plus cetuximab is a suitable first-line treatment optionWould you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/Pp7oAI9JW4A
Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/gi-connect/programmes/braf-mutated-crc-testing-treatment/
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/giconnect
X: https://x.com/giconnectInfo
This content is intended for healthcare professionals outside of the UK only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre
This podcast was developed by https://cor2ed.com/
Published November 2024
Subscribe to this channel to stay up to date with new Independent Edu...
-
In this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared decision-making, between patient and physician.
The speakers discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no standard therapy for patients with NETs. Finally, they look at some of the studies reporting patient preferences, and how the data can be used to inform patient decisions.
Prefer to watch and listen?
Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/?media=1Watch the full video on YouTube https://youtu.be/2JYuPhc2jHg
Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k
Follow us on social media
LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect
X: https://x.com/net_connectinfo
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen
This podcast is developed by cor2ed.com
Published July 2024
-
Episodes manquant?
-
In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the importance of communication and collaboration during consultations. This can include how to make a patient feel as comfortable and in control as possible, as well as recognising their goals and concerns.
The speakers share their real-life experiences of what makes a good consultation, from the perspectives of both a patient and a physician. They also explore the importance of support networks, individualising treatment, and the impact of NET and NET treatment options in daily life.
NETs are complex, rare diseases. Optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. Are you aware of how healthcare practitioners and patients can share decision- making? Or the recent data on how patients prefer to receive treatment?
In this first episode of a two-part podcast series, Dr Mohid S Khan and NET patient Sally Jenkins discuss shared decision-making in NET consultations and ways to help the patient in their journey.
Prefer to watch and listen?
Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/Watch the full video on YouTube https://youtu.be/YgqrEnSePWg
Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k
Follow us on social media
LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect
X: https://x.com/net_connectinfo
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen
This podcast is developed by cor2ed.com
Published July 2024
-
In the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living with NETs and future developments in the field which may help to improve patient outcomes. The episode includes information on different treatment options and modalities, and well as best practice on identifying which patients may benefit most from particular treatments using available biomarkers.
Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-2/
Or go to the video on YouTube: https://youtu.be/zd_JvUmIhFg
We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen.
This podcast is developed by cor2ed.com
-
In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient pathways, as well as look to future developments.
NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional differences can impact these? In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, patient pathways, as well as look to future developments.
Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-1/
Or go to the video on YouTube: https://youtu.be/6fKAxS4u-2o
We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen.
This podcast is developed by cor2ed.com
-
Do you understand the needs of different patient groups with colorectal cancer? Do you know about the barriers to treatment experienced by different ethnicities, socioeconomic groups and younger patients? In this insightful podcast facilitated by Oncology Brothers Drs Rahul and Rohit Gosain, Prof Tanios Bekaii-Saab and Ms Deneen Richmond provide their perspectives as a practising oncologist and a cancer survivor.
They discuss the different methods of communication required to build trust in patients from specific ethnic groups (African American, Hispanic and Asian American). They also talk about the unique challenges experienced by younger patients with colorectal cancer. Throughout the podcast the experts emphasise the importance of screening to facilitate early diagnosis and treatment.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/patient-populations-colorectal-cancer/
Or go to the video on YouTube: https://youtu.be/o-lr54-D9_g
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.
This educational podcast is developed by cor2ed.com
-
What are the challenges and considerations when using real-world evidence to inform your clinical practice? How can data from real-world studies be used to complement data from clinical trials?
In this podcast, GI oncologists Prof. Tanios Bekaii-Saab and Prof. Shubham Pant discuss how to interpret real-world evidence in later line metastatic colorectal cancer. They also discuss data from ASCO GI 2024 and how these results can be used to inform treatment decisions.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/real-world-evidence-mcrc/
Or go to the video on YouTube: https://youtu.be/knQcsWVqcSA
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.
This educational podcast is developed by cor2ed.com
-
¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de ovario, y cómo podemos solucionarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Usted está viendo el tercer episodio de una serie de podcast de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará a la profesora adjunta Martina Murphy (médica oncóloga) y a la profesora adjunta Caterina Marchiò (anatomopatóloga) hablar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores en el cáncer de ovario.
A medida que se desarrolla la conversación, las expertas explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de ovario y hablan sobre los mejores métodos para minimizar las dificultades preanalíticas.
¿Prefiere ver el video mientras escucha?
Vea el video de la conversación de los expertos y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-ovario-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/
O acceda al video en YouTube: https://youtu.be/HnYacC0wZp0
Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP). Puede obtener más información sobre la AMP en www.amp.org.
Los expertos médicos en este podcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics. Este podcast fue creado por cor2ed.com
-
Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de ovário e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está assistindo à parte 3 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá a Professora Adjunta Martina Murphy (oncologista) e a Professora Adjunta Caterina Marchiò (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de ovário.
Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de ovário e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.
Prefere assistir enquanto escuta?
Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-ovario-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/
Ou veja o vídeo no YouTube: https://youtu.be/tiUgtzqMD-Q
Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP). Saiba mais sobre a AMP em www.amp.org
Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics. Este podcast é desenvolvido pela cor2ed.com
-
¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de próstata, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Está escuchando la parte 1 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará al especialista en genómica del cáncer genitourinario, el Dr. Alexander Wyatt, y al oncólogo médico, el Dr. Petros Grivas, profundizar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores en el cáncer de próstata.
A medida que se desarrolla la conversación, los expertos explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de próstata y hablan sobre los mejores métodos prácticos que contribuyen a minimizar las dificultades preanalíticas.
¿Prefiere ver el video mientras escucha?
Vea el video de la conversación de los expertos y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-prostata-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/
O acceda al video en YouTube: https://youtu.be/WR9pX3kNao0
Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP) y de la Asociación Nacional de Coaliciones de Cáncer de Próstata (NASPCC). Puede obtener más información sobre la AMP en https://amp.org y la NASPCC en https://naspcc.org.
Los expertos médicos en este podcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics.
Este pódcast fue creado por cor2ed.com
-
Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de próstata e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está ouvindo a parte 1 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá o especialista em genoma do câncer geniturinário, Dr. Alexander Wyatt, e o oncologista, Dr. Petros Grivas, esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de próstata.
Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de próstata e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.
Prefere assistir enquanto escuta?
Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-prostata-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/
Ou veja o vídeo no YouTube: https://youtu.be/Pp-2qMSaOPU
Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP) e da Aliança Nacional das Coalizões Estaduais de Câncer de Próstata (NASPCC). Saiba mais sobre a AMP em https://amp.org e sobre a NASPCC em https://naspcc.org
Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics.
Este podcast é desenvolvido pela cor2ed.com
-
¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de pulmón, y cómo podemos superarlos? ¿Por qué es importante identificar las alteraciones genéticas?
Está viendo la parte 2 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.
En este episodio, escuchará a la Dra. Bruna Pellini (médica oncóloga) y al Dr. Semir Vranić (anatomopatólogo) profundizar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores del cáncer de pulmón.
A medida que se desarrolla la conversación, los expertos explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de pulmón y hablan sobre los mejores métodos prácticos que contribuyen a minimizar las dificultades preanalíticas.
¿Prefiere ver el video mientras escucha?
Vea el video de la conversación de los especialistas y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-pulmon-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/
O acceda al video en YouTube: https://youtu.be/LSyhFcVatSI
Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP). Puede obtener más información sobre la AMP en www.amp.org.
Los expertos médicos en este pódcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics. Este pódcast fue creado por cor2ed.com
-
Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de pulmão e como podemos superá-los? Qual a importância de detectar alterações genéticas?
Você está assistindo à parte 2 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.
Neste episódio, você ouvirá a Dra. Bruna Pellini (oncologista) e Semir Vranić (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de pulmão.
Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de pulmão e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.
Prefere assistir enquanto escuta?
Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-pulmao-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/
Ou veja o vídeo no YouTube: https://youtu.be/lmwt0UVitF4
Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP). Saiba mais sobre a AMP em www.amp.org
Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics. Este podcast é desenvolvido pela cor2ed.com
-
What treatment options are available for patients with metastatic colorectal cancer who have already progressed through multiple lines of therapy? How can we select the right treatment for the right patient?
Medical oncologists Assoc. Prof. Gerald Prager (Austria) and Dr Victor Hugo Fonseca de Jesus draw from their own clinical expertise and data from clinical trials to provide their perspectives on these questions. They discuss how to manage side effects from available treatments to maximise survival benefit whilst maintaining quality of life and consider what the future holds for later-line treatment in metastatic colorectal cancer.
Prefer to watch as well as listen?
Watch a video
of the experts in conversation and download the full transcript on the COR2ED
website: https://cor2ed.com/gi-connect/programmes/patient-outcomes-mcrc/
Or go to the video on YouTube: https://youtu.be/ftjskGynDIc
We are pleased to share that this podcast is endorsed by Bayer
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.
This educational podcast is developed by cor2ed.com
-
Why is it important to perform comprehensive molecular testing in non-small cell lung cancer to look beyond the obvious mutations? Which biomarker tests are best andwhen should testing be performed?
In this podcast episode, you’ll hear Prof. Mark Socinski (medical oncologist) and Prof. Frédérique Penault-Llorca (pathologist) discuss why perseverance with molecular testing pays off in non-small cell lung cancer (NSCLC).
As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in NSCLC, which biomarker testing approaches should be considered standard of care, and the importance of close collaboration with the pathologist and other members of the multidisciplinary team for optimal patient care.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website:https://cor2ed.com/precision-oncology-connect/programmes/precision-oncology-nsclc/
Or go to the video on YouTube: https://youtu.be/Gn_sjyexreM
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. This podcast is developed by cor2ed.com
-
What are the common pre-analytical phase challenges in ovarian cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are watching part 3 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain.
In this episode, you’ll hear Assoc. Prof. Martina Murphy (medical oncologist) and Assoc. Prof. Caterina Marchiò (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in ovarian cancer.
As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in ovarian cancer and discuss best practice approaches to help minimise pre-analytical challenges.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/ovarian-cancer-preanalytical-challenges-biomarker/
Or go to the video on YouTube: https://youtu.be/EabQZ4CKf5s
We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP). You can find out more about AMP at www.amp.org
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics. This podcast is developed by cor2ed.com.
-
What are the common pre-analytical phase challenges in lung cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are watching part 2 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain.
In this episode, you’ll hear Dr Bruna Pellini (medical oncologist) and Semir Vranić (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in lung cancer.
As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in lung cancer and discuss best practice approaches to help minimise pre-analytical challenges.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/lung-cancer-preanalytical-challenges-biomarker/
Or go to the video on YouTube: https://youtu.be/OG7pWLZ5KMk
We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP). You can find out more about AMP at www.amp.org
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics. This podcast is developed by cor2ed.com.
-
Treatment of advanced colorectal cancer should be considered a continuum of care and patients should be offered as many life prolonging therapies as possible. Do you know how to sequence later line therapies in metastatic colorectal cancer?
In this podcast, gastrointestinal oncologists Dr Thomas Winder (Austria and Switzerland) and Dr Mark Lewis (USA) discuss the treatment of metastatic colorectal cancer, third line and beyond. They discuss the sequence of later line treatments regorafenib, TAS-102, bevacizumab and fruquintinib and refer to key clinical trials such as SUNLIGHT, CORRECT, RECOURSE, FRESCO-2 and ReDOS. They emphasise the importance of balancing treatment efficacy whilst considering adverse event profiles to maintain the patient’s quality of life.
The experts also discuss biomarkers used in a number of molecularly selected trials such as HER2 in the HERACLES (trastuzumab plus lapatininb), MOUNTAINEER (tucatinib plus trastuzumab) and DESTINY-CRC02 (trastuzumab deruxtecan) studies and KRAS G12c in the CODEBREAK 300 study (sotorasib plus panitumumab).
-
What are tumour agnostic cancer treatments and which biomarkers do they target?
Join Prof. David Hong (Medical Oncologist at MD Anderson Cancer Center, Houston, Texas, United States) and Dr Tracy L Stockley (Pathologist and Geneticist at University Health Network, Toronto, Canada) as they deep dive into the topic of tumour agnostic therapies in this video podcast.
As the conversation unfolds, the precision oncology experts explore the issues and challenges associated with developing tumour agnostic therapies and discuss how these treatments differ from others.
Listen to deepen your understanding of:
Biomarker targets associated with tumour agnostic therapiesWhich tumours carry these gene alterationsAppropriate genetic testing strategies to detect these biomarkersPrefer to watch as well as listen?
Watch a video of the experts in conversation and get the clinical takeaways and podcast transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/tumour-agnostic-therapies/
Or go to the video on YouTube: https://www.youtube.com/watch?v=AO33Yv0RTVs
Find out more about the experts Prof. David Hong and Dr Tracy L Stockley
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer and is developed by cor2ed.com.
-
What are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic alterations?
You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.
In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.
As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in prostate cancer and discuss best practice approaches to help minimise pre-analytical challenges.
Prefer to watch as well as listen?
Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/prostate-cancer-preanalytical-challenges-biomarker/
Or go to the video on YouTube: https://www.youtube.com/watch?v=Sxzw1SX3nao
We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP) and The National Alliance of State Prostate Cancer Coalitions (NASPCC). You can find out more about AMP at https://amp.org and NASPCC at https://naspcc.org
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics.
This podcast is developed by cor2ed.com.
- Montre plus
